Nanogen forms personalised antidepressants deal
This article was originally published in Clinica
Executive Summary
Nanogen and Pathway Diagnostics have formed a nonexclusive, worldwide licence agreement under which Nanogen will develop diagnostic products that detect genetic variations linked with responses to antidepressant and antipsychotic therapeutics.